

Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence MidCity Place 71 High Holborn London WC1V 6NA

2<sup>nd</sup> October 2009

Dear Sir or Madam,

Multi Technology Appraisal: Bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma.

Macmillan Cancer Support endorse all the views and comments put forward in this statement by Myeloma UK.

If you require further information please contact me on or at

Yours sincerely,

Macmillan Cancer Support